Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Dynavax Technologies (DVAX)

Dynavax Technologies (DVAX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,054,210
  • Shares Outstanding, K 114,588
  • Annual Sales, $ 46,550 K
  • Annual Income, $ -75,240 K
  • 60-Month Beta 1.23
  • Price/Sales 22.84
  • Price/Cash Flow N/A
  • Price/Book 10.88
Trade DVAX with:

Options Overview

Details
  • Implied Volatility 76.03%
  • Historical Volatility 38.02%
  • IV Percentile 10%
  • IV Rank 7.28%
  • IV High 213.51% on 02/01/21
  • IV Low 65.24% on 06/16/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 47
  • Volume Avg (30-Day) 1,331
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 41,400
  • Open Int (30-Day) 52,238

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.04
  • Number of Estimates 3
  • High Estimate 0.08
  • Low Estimate -0.12
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +85.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.88 +6.70%
on 07/08/21
10.35 -8.46%
on 07/01/21
+0.19 (+1.99%)
since 06/28/21
3-Month
7.09 +33.64%
on 05/11/21
10.56 -10.27%
on 04/29/21
-0.85 (-8.28%)
since 04/28/21
52-Week
3.58 +164.66%
on 10/29/20
11.84 -19.97%
on 04/19/21
+0.87 (+10.05%)
since 07/28/20

Most Recent Stories

More News
Dynavax to Report Second Quarter 2021 Financial Results and Host Conference Call on August 4, 2021

/PRNewswire/ -- (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2021 financial results on , after the U.S. financial markets...

DVAX : 9.47 (+2.93%)
Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate

and , /PRNewswire/ --  (Dynavax, Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines and  (BE), a -based vaccine and pharmaceutical company, today announced...

DVAX : 9.47 (+2.93%)
United States $30 Billion Vaccines Market to 2027 Featuring Pfizer, Merck, Grifols, Sanofi Pasteur, Seqirus, AstraZeneca, GlaxoSmithKline, Dynavax Technologies

/PRNewswire/ -- The report has been added to offering.

DVAX : 9.47 (+2.93%)
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 51,000 shares of Dynavax common stock as inducements...

DVAX : 9.47 (+2.93%)
Eyes Shift to the Healthcare Industry After the Pandemic Prompts a Reconsideration

/PRNewswire/ -- While the economy is slowly coming back to normal, concerns over the hyper-transmissible delta variant are rising. According to the CDC, the number of new cases in rose 10% this week....

PFE : 43.42 (+3.14%)
TOMDF : 0.0270 (-0.74%)
DVAX : 9.47 (+2.93%)
SRNE : 8.44 (+4.33%)
AGEN : 5.21 (+4.62%)
Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate

DVAX : 9.47 (+2.93%)
Slow Trading Can't Stop S&P, NASDAQ From Setting New Records

Slow Trading Can't Stop S&P, NASDAQ From Setting New Records

EVC : 6.24 (-0.48%)
MU : 75.72 (+2.02%)
WGO : 69.33 (+1.39%)
NTAP : 78.24 (+0.36%)
KBH : 41.14 (-0.41%)
FB : 371.73 (+1.07%)
GBTC : 34.5330 (+4.65%)
TWST : 117.72 (+5.61%)
DVAX : 9.47 (+2.93%)
VIVO : 19.94 (+1.48%)
EDIT : 41.44 (+5.53%)
Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ --  (Nasdaq: DVAX) today announced that, in connection with the appointment of John Slebir as Senior Vice President, General Counsel on , the Company granted him a non-statutory stock option...

DVAX : 9.47 (+2.93%)
Dynavax to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

/PRNewswire/ --  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that , Chief Executive Officer, will present virtually at the Goldman...

DVAX : 9.47 (+2.93%)
Oligonucleotide Therapy Global Market Report 2021: COVID 19 Growth And Change to 2030

Reportlinker.com announces the release of the report "Oligonucleotide Therapy Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06090627/?utm_source=GNW

DVAX : 9.47 (+2.93%)
IONS : 37.05 (+1.87%)
JAZZ : 175.60 (+1.09%)
MRK : 78.30 (+0.58%)
MGEN : 23.01 (-0.09%)
SRPT : 68.33 (+3.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development...

See More

Key Turning Points

3rd Resistance Point 9.62
2nd Resistance Point 9.47
1st Resistance Point 9.34
Last Price 9.47
1st Support Level 9.06
2nd Support Level 8.91
3rd Support Level 8.77

See More

52-Week High 11.84
Last Price 9.47
Fibonacci 61.8% 8.68
Fibonacci 50% 7.71
Fibonacci 38.2% 6.74
52-Week Low 3.58

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar